Melanotan I (afamelanotide) is a synthetic analog of α-melanocyte stimulating hormone that selectively targets MC1 receptors to stimulate melanin production.
Last reviewed: 2026-08-18
Also known as
Status: Research peptide - not approved for human consumption; FDA-approved SCENESSE® implant exists for rare conditions
Full composition (formula, molecular weight, sequence) in Quick Facts →
Afamelanotide (the approved 'melanotan I' analog) is FDA-approved (2019) and EMA-approved for erythropoietic protoporphyria; a placebo-controlled trial (NEJM 2015) showed increased pain-free light exposure and improved quality of life in EPP patients.
Preclinical models demonstrate MC1R-mediated eumelanin synthesis and photoprotective effects.
In vitro studies show NDP-MSH activation of the melanocortin-1 receptor stimulates melanogenesis in melanocytes.
Use of unregulated 'melanotan' products for cosmetic tanning is not FDA-approved; safety (e.g., changes in nevi, melanoma risk) is not established, and dermatology organizations have warned against unregulated use.
In a randomized, double-blind, placebo-controlled trial, afamelanotide increased pain-free light exposure and reduced phototoxic symptoms in patients with erythropoietic protoporphyria.
FDA approved afamelanotide (Scenesse) to increase pain-free light exposure in adults with erythropoietic protoporphyria.
No side effects data available yet.
This peptide may have limited safety data.
Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.
0.25mg
Research protocols are for educational purposes only. Always consult qualified medical professionals.
The approved drug Scenesse is afamelanotide, a pharmaceutical form of 'melanotan I' (NDP-MSH), approved only for erythropoietic protoporphyria — not for tanning.
Unregulated melanotan use for tanning is not approved; safety data are lacking and dermatology organizations have issued warnings.
Safety Profile Assessment (2006)
(2006)
MT-I Photoprotection Study (2004)
(2004)
Tanning Efficacy Comparison (2003)
(2003)
Mechanism
Subcutaneous injection delivers Melanotan I directly into systemic circulation with 100% bioavailability. 30-minute half-life requires multiple daily injections for sustained MC1R activation and melanin production.
Research peptide - not approved for human consumption, sold for research purposes only. Start with lower doses to assess individual tolerance and response. Monitor moles and skin changes - perform regular self-examinations. Use proper sterile injection technique to prevent infections. Maintain UV protection despite enhanced tanning - still risk of overexposure.
1.Safety Profile Assessment (2006)
(2006)
2.MT-I Photoprotection Study (2004)
(2004)
3.Tanning Efficacy Comparison (2003)
(2003)